ArticleHaematologica2021
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Jumpei Teramachi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papercites it
ArticleHaematologica2021
Jumpei Teramachi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.